| Renal transporters in drug development KM Morrissey, SL Stocker, MB Wittwer, L Xu, KM Giacomini Annual review of pharmacology and toxicology 53, 503-529, 2013 | 336 | 2013 |
| Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol RO Day, GG Graham, M Hicks, AJ McLachlan, SL Stocker, KM Williams Clinical pharmacokinetics 46, 623-644, 2007 | 226 | 2007 |
| Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin WH Chung, WC Chang, SL Stocker, CG Juo, GG Graham, MHH Lee, ... Annals of the rheumatic diseases 74 (12), 2157-2164, 2015 | 216 | 2015 |
| Clinical pharmacokinetics in kidney disease: fundamental principles TN Lea-Henry, JE Carland, SL Stocker, J Sevastos, DM Roberts Clinical journal of the American society of nephrology 13 (7), 1085-1095, 2018 | 214 | 2018 |
| Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance MJ Zamek‐Gliszczynski, ME Taub, PP Chothe, X Chu, KM Giacomini, ... Clinical Pharmacology & Therapeutics 104 (5), 890-899, 2018 | 213 | 2018 |
| The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin SL Stocker, KM Morrissey, SW Yee, RA Castro, L Xu, A Dahlin, ... Clinical Pharmacology & Therapeutics 93 (2), 186-194, 2013 | 211 | 2013 |
| Researchers’ views on, and experiences with, the requirement to obtain informed consent in research involving human participants: a qualitative study A Xu, MT Baysari, SL Stocker, LJ Leow, RO Day, JE Carland BMC medical ethics 21, 1-11, 2020 | 167 | 2020 |
| Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting A Broeker, M Nardecchia, KP Klinker, H Derendorf, RO Day, DJ Marriott, ... Clinical Microbiology and Infection 25 (10), 1286. e1-1286. e7, 2019 | 129 | 2019 |
| Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin EC Chen, X Liang, SW Yee, EG Geier, SL Stocker, L Chen, KM Giacomini Molecular pharmacology 88 (1), 75-83, 2015 | 113 | 2015 |
| Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens DM Roberts, J Sevastos, JE Carland, SL Stocker, TN Lea-Henry Clinical Journal of the American Society of Nephrology 13 (8), 1254-1263, 2018 | 80 | 2018 |
| Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin S Goswami, SW Yee, S Stocker, JD Mosley, M Kubo, R Castro, JA Mefford, ... Clinical Pharmacology & Therapeutics 96 (3), 370-379, 2014 | 77 | 2014 |
| Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout SL Stocker, GG Graham, AJ McLachlan, KM Williams, RO Day The Journal of Rheumatology 38 (5), 904-910, 2011 | 72 | 2011 |
| Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures A Dahlin, E Geier, SL Stocker, CD Cropp, E Grigorenko, M Bloomer, ... Molecular pharmaceutics 10 (2), 650-663, 2013 | 70 | 2013 |
| Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? MH Lee, SL Stocker, J Anderson, EJ Phillips, D Nolan, KM Williams, ... Internal medicine journal 42 (4), 411-416, 2012 | 64 | 2012 |
| The effect of famotidine, a MATE1-selective inhibitor, on the pharmacokinetics and pharmacodynamics of metformin JE Hibma, AA Zur, RA Castro, MB Wittwer, RJ Keizer, SW Yee, ... Clinical pharmacokinetics 55, 711-721, 2016 | 58 | 2016 |
| Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: a systematic review and meta-analysis TY Milder, SL Stocker, C Abdel Shaheed, L McGrath-Cadell, ... Journal of clinical medicine 8 (1), 45, 2019 | 55 | 2019 |
| Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8) SW Yee, AN Nguyen, C Brown, RM Savic, Y Zhang, RA Castro, CD Cropp, ... Journal of pharmaceutical sciences 102 (9), 3451-3457, 2013 | 54 | 2013 |
| A model averaging/selection approach improves the predictive performance of model‐informed precision dosing: vancomycin as a case study DW Uster, SL Stocker, JE Carland, J Brett, DJE Marriott, RO Day, ... Clinical Pharmacology & Therapeutics 109 (1), 175-183, 2021 | 52 | 2021 |
| Clinical standards for the dosing and management of TB drugs JWC Alffenaar, SL Stocker, LD Forsman, A Garcia-Prats, SK Heysell, ... The International Journal of Tuberculosis and Lung Disease 26 (6), 483-499, 2022 | 48 | 2022 |
| Characterization of ADME gene variation in 21 populations by exome sequencing DH Hovelson, Z Xue, M Zawistowski, MG Ehm, EC Harris, SL Stocker, ... Pharmacogenetics and genomics 27 (3), 89-100, 2017 | 47 | 2017 |
Richard O. DayProfessor of Clinical Pharmacology, University of New South Wales and St Vincent's Hospital, SydneyPotvrđena adresa e-pošte na unsw.edu.au
